Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Entecavir · 1 trial · 2 indications
Baseline HBV DNA is defined as the last pre-dose assessment of HBV DNA.
| Arm | Type | Description |
|---|---|---|
| Telbivudine | EXPERIMENTAL | - |
| Entecavir | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Entecavir | DRUG | Entecavir 0.5 mg once daily for 12 weeks. |
| Telbivudine | DRUG | Telbivudine 600 mg once daily for 12 weeks. |
Inclusion Criteria: * Male or female, 18-70 years of age with documented compensated hepatitis B "e" antigen (HBeAg)-positive chronic hepatitis B * Able to comply with study regimen and provide written informed consent Exclusion Criteria: * Pregnant or breastfeeding * Unwilling to use double barr...
Entecavir is used for the treatment of Hepatitis B, specifically chronic Hepatitis B. It is a small molecule being developed by Novartis AG. The drug is currently in Phase 3 clinical development for this indication.
Entecavir is a small molecule antiviral agent. It works by inhibiting the hepatitis B virus polymerase, thereby suppressing viral replication. This mechanism helps reduce the viral load in patients with chronic Hepatitis B infection.
Entecavir is being developed by Novartis AG, a multinational pharmaceutical company. Novartis is listed on the stock exchange under the ticker symbol NVS. The drug is currently in Phase 3 clinical trials for Hepatitis B.
Entecavir is in Phase 3 clinical development. It is an investigational drug for the treatment of Hepatitis B and has not yet been approved by regulatory authorities. One Phase 3 trial has been completed.
Entecavir has one completed Phase 3 clinical trial with the identifier NCT00412529. This trial was a viral kinetics study comparing telbivudine and entecavir in adults with chronic Hepatitis B. The study enrolled 44 participants and was conducted in South Korea.
No, Entecavir is not the same as telbivudine. They are different antiviral drugs used for Hepatitis B. In a clinical trial, they were compared against each other to evaluate their viral kinetics in patients with chronic Hepatitis B.